TSHA Q3 2024 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena

TSHATaysha Gene Therapies, Inc.

$1B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-62.3% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$26M-1448.4% margin

Net Income

-$26M-1427.5% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

+60.8%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$22M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$180M

Total Liabilities

$91M

Stockholders' Equity

$89M

Cash & Equivalents

$158M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$5M	-62.3%
Gross Profit	$2M	$4M	-59.5%
Operating Income	-$26M	-$16M	-65.7%
Net Income	-$26M	-$117M	+78.2%